Skip to main content
NVDA+0.35%AAPL-0.01%GOOGL-0.61%MSFT+0.11%AMZN+0.12%TSM+0.96%SPCX+5.15%META+0.13%AVGO+0.07%TSLA+0.10%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.49%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.75%NZDUSD-1.68%AUDUSD-1.19%EURUSD-1.15%USDCHF+1.14%GBPUSD-1.07%USDTHB+1.06%CADJPY+0.93%NZDCAD-0.86%USDCAD+0.84%CHFJPY+0.72%GBPJPY+0.63%GBPNZD+0.61%EURJPY+0.57%AUDJPY+0.56%NZDCHF-0.55%EURNZD+0.53%AUDNZD+0.50%GBPTRY+0.41%EURCAD-0.36%AUDCAD-0.35%GBPHKD+0.32%USDTRY+0.32%CADCHF+0.30%GBPMXN-0.28%GBPCAD-0.25%USDILS+0.16%GBPAUD+0.09%NZDMXN+0.07%USDCNH+0.07%NZDJPY+0.06%AUDSGD-0.06%USDZAR+0.06%EURAUD+0.05%EURGBP-0.05%AUDCHF-0.05%USDCOP-0.04%GBPSGD-0.04%GBPCHF+0.03%NZDSGD+0.03%USDSGD-0.03%USDMXN+0.03%USDHKD+0.02%EURSGD-0.02%SGDJPY+0.02%EURCHF0.00%CHFSGD0.00%EURPLN0.00%EURSEK0.00%GBPZAR0.00%PLNJPY0.00%USDSEK0.00%EURNOK0.00%EURDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%EURCZK0.00%USDPLN0.00%NOKJPY0.00%CHFNOK0.00%USDNOK0.00%USDDKK0.00%XPTUSD+0.50%USOIL-0.34%XNGUSD+0.23%XAGUSD-0.16%GAGUSD-0.16%GAUUSD-0.14%XAUUSD-0.14%HG1+0.07%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.30%ETHUSD+0.05%USDTUSD+0.01%XRPUSD+0.24%SOLUSD+1.16%TRXUSDT+0.85%ZECUSDT+19.00%DOGEUSD+0.39%XMRUSDT-3.33%LINKUSD+0.11%XLMUSD+2.39%BCHUSDT+0.64%UNIUSD+0.99%LTCUSD+0.01%TONUSD+29.54%HBARUSDT-1.78%SUIUSD+2.48%TAOUSDT+0.91%AAVEUSD-2.45%DOTUSDT+6.24%ICPUSDT+1.16%ONDOUSDT+3.23%WLDUSDT+1.83%ARBUSDT+7.51%ATOMUSDT-1.34%JUPUSDT-1.19%INJUSDT-1.15%STXUSDT+2.00%FETUSDT+2.77%PYTHUSDT-1.32%TIAUSDT+2.70%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.74%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+1.05%IOTAUSDT-0.87%AXSUSDT+0.03%FARTCOINUSDT-0.86%EOSUSDT-0.44%DYDXUSDT-0.14%ORDIUSDT+2.66%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%NVDA+0.35%AAPL-0.01%GOOGL-0.61%MSFT+0.11%AMZN+0.12%TSM+0.96%SPCX+5.15%META+0.13%AVGO+0.07%TSLA+0.10%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.49%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.75%NZDUSD-1.68%AUDUSD-1.19%EURUSD-1.15%USDCHF+1.14%GBPUSD-1.07%USDTHB+1.06%CADJPY+0.93%NZDCAD-0.86%USDCAD+0.84%CHFJPY+0.72%GBPJPY+0.63%GBPNZD+0.61%EURJPY+0.57%AUDJPY+0.56%NZDCHF-0.55%EURNZD+0.53%AUDNZD+0.50%GBPTRY+0.41%EURCAD-0.36%AUDCAD-0.35%GBPHKD+0.32%USDTRY+0.32%CADCHF+0.30%GBPMXN-0.28%GBPCAD-0.25%USDILS+0.16%GBPAUD+0.09%NZDMXN+0.07%USDCNH+0.07%NZDJPY+0.06%AUDSGD-0.06%USDZAR+0.06%EURAUD+0.05%EURGBP-0.05%AUDCHF-0.05%USDCOP-0.04%GBPSGD-0.04%GBPCHF+0.03%NZDSGD+0.03%USDSGD-0.03%USDMXN+0.03%USDHKD+0.02%EURSGD-0.02%SGDJPY+0.02%EURCHF0.00%CHFSGD0.00%EURPLN0.00%EURSEK0.00%GBPZAR0.00%PLNJPY0.00%USDSEK0.00%EURNOK0.00%EURDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%EURCZK0.00%USDPLN0.00%NOKJPY0.00%CHFNOK0.00%USDNOK0.00%USDDKK0.00%XPTUSD+0.50%USOIL-0.34%XNGUSD+0.23%XAGUSD-0.16%GAGUSD-0.16%GAUUSD-0.14%XAUUSD-0.14%HG1+0.07%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.30%ETHUSD+0.05%USDTUSD+0.01%XRPUSD+0.24%SOLUSD+1.16%TRXUSDT+0.85%ZECUSDT+19.00%DOGEUSD+0.39%XMRUSDT-3.33%LINKUSD+0.11%XLMUSD+2.39%BCHUSDT+0.64%UNIUSD+0.99%LTCUSD+0.01%TONUSD+29.54%HBARUSDT-1.78%SUIUSD+2.48%TAOUSDT+0.91%AAVEUSD-2.45%DOTUSDT+6.24%ICPUSDT+1.16%ONDOUSDT+3.23%WLDUSDT+1.83%ARBUSDT+7.51%ATOMUSDT-1.34%JUPUSDT-1.19%INJUSDT-1.15%STXUSDT+2.00%FETUSDT+2.77%PYTHUSDT-1.32%TIAUSDT+2.70%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.74%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+1.05%IOTAUSDT-0.87%AXSUSDT+0.03%FARTCOINUSDT-0.86%EOSUSDT-0.44%DYDXUSDT-0.14%ORDIUSDT+2.66%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%
EM

Embecta Corp. (EMBC)

NASDAQHealthcare

$5.13
+$0.04 (+0.8%)
Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$5.09
Day Range$5.09 - $5.29
Avg. Volume (3M)1.2M
Market Cap$304.3M
P/E Ratio3.4
52 Week Range
$2.77$15.55
Next EarningsIn 69 daysNov 24, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$271.7M100%
Gross Profitminus cost of goods$153.3M56%
Operating Incomeminus R&D and overhead$48.7M18%
Net Incomeminus taxes and the rest$21.1M8%

In plain terms: out of every $100 in revenue, Embecta Corp. keeps $8 as net profit.

Fundamentals & Financials

Revenue (TTM)
$1B
Net Income (TTM)
$87.5M
EPS (TTM)
$1.49
ROA (TTM)
6.92%
Current Ratio
1.68
Dividend Yield
0.31%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+6.0%Q1 2026$0.71
-35.7%Q2 2026$0.27
+110.7%Q3 2026$0.56
Next

Nov 24

in 69 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +110.7%

Embecta Corp. beat consensus on both revenue and adjusted EPS in the third fiscal quarter of 2026, reported Aug. 7, as revenue fell 8% to about $271.7 million from about $295.5 million a year ago. Revenue came in above the $254.5 million estimate by roughly 7%, while adjusted EPS of $0.56 topped the $0.27 consensus by about 111% and was down 50% from $1.12 a year earlier. Net income declined 54% to about $21.1 million from about $45.5 million a year ago, even as gross margin held near 52% and operating margin stayed around 18%. International remained the largest market at about $150.9 million, rising 12%, while U.S. revenue fell 25% to about $120.8 million. Operating cash flow was about $41.8 million, and the company repurchased about $3.9 million of stock and paid about $600,000 in dividends. Consensus for the next period calls for EPS of $0.34 on revenue of $283.6 million.

View full earnings history

About Embecta Corp.

Embecta Corp. is a healthcare company focused on diabetes care, making injection products and related tools for people living with the disease. Listed on the NASDAQ as EMBC, Embecta sells pen needles, syringes, safety devices, and digital applications, and it generated $1.1 billion of revenue in FY2025.

Name
Embecta Corp.
CEO
Devdatt Kurdikar
Industry
Healthcare
Year Founded
1924
Employees
1,850

Today's Snapshot

AI-generated

The day ended with EMBC 0.8% higher at 5.13, while its sector was flat. Trading was lighter than usual, with volume about two-thirds of its usual level.

Trading Volume

Below 10d avg (1.1M)

717.6K

vs S&P 500 Today

Outperforming Market

+1.37%

Updated: September 16, 2026 at 20:44 UTC

Technical Indicators

2 Buy3 Neutral3 Sell
EMBC is exhibiting a modestly bearish stance as the stock trades beneath short-term averages and well below the 200-day level, signaling longer-term resistance despite some medium-range averages sitting below the current price. Momentum and MACD are tepid while RSI is near neutral, and ADX indicates a defined trend is present. On-balance volume shows some accumulation signals against a negative absolute base, creating mixed conviction, while ATR points to elevated relative volatility. Collectively this favors a sell posture given the dominance of down‑side pressure versus limited short-term support. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$4.74 - $7.70
    Sell
  • RSI (14)53.54
    Neutral
  • Stochastic %K (14, 3, 3)31.83
    Neutral
  • MACD Level (12, 26)0.18
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.